Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
The companies will co-develop a mass-market central nervous system program using Insilico’s AI platform and CMS’s R&D and commercialization expertise.
- On Sunday, July 12, 2026, Insilico Medicine and China Medical System Holdings Limited announced an additional AI-powered drug discovery collaboration targeting a central nervous system indication with an innovative mechanism identified by PandaOmics.
- This deal follows an initial collaboration announced three months ago, which both companies described as seamless and productive since inception. The partnership aims to accelerate delivery of clinically meaningful innovations to patients with greater speed and quality.
- The program combines Insilico's AI-powered drug discovery platform with CMS's clinical development expertise and commercialization network. Together they focus on identifying innovative mechanisms of action to streamline molecules from "proof of concept" to therapy.
- "CMS is deeply impressed by Insilico Medicine's capability and productivity in AI drug discovery," Chairman Lam Kong, Chief Executive Officer, President and Executive Director of CMS, said. Insilico Co-CEO Feng Ren, PhD, added the partnership "streamlines the development of high-potential drugs, enhancing translational efficiency."
- Insilico, listed on the Hong Kong Exchange in December 2025, forecasts record H1 2026 revenue between approximately $102.5 million and $106.5 million, driven by its expansive 40+ program pipeline and strategic partnerships with biopharmas.
47 Articles
47 Articles
China Medical System to pay Insilico up to $177 million for nervous system work - Regional Media News
SHANGHAI, July 13 (Reuters) - Drugmaker China Medical System will pay Insilico Medicine up to about 1.2 billion yuan ($177 million) in milestone payments for a research and development programme in the central nervous system disease field, the Boston-based drug discovery firm said. • The collaboration targets a "mass-market indication in central nervous system", Insilico said in a statement. • The two firms will "jointly advance the co-developme…
InsideNoVA.com
Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
SHANGHAI, July 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product…
Insilico Medicine and CMS Expand AI Collaboration for CNS Disease Research
Shanghai-based Insilico Medicine and China Medical System Holdings Limited (CMS) have intensified their collaborative efforts in the realm of AI-driven drug discovery, this time focusing on central nervous system (CNS) disorders. This fresh partnership leverages Insilico’s advanced generative artificial intelligence platform alongside CMS’s seasoned R&D and commercialization expertise to accelerate the pipeline development of innovative therapeu…
Insilico Medicine and CMS expand AI collaboration on CNS diseases
SHANGHAI, July 13, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collabor…
StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III
Insilico Medicine (Hong Kong Exchange: 3696), an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past week. Insilico said it expects to finish the first half of 2026 …
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
